Philip McCarthy, MD
My research interests are devoted to developing novel intensive and reduced intensity allogeneic and autologous hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. I have over 20 years of experience treating HSCT patients and directing clinical and translational HSCT research studies. I have served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous HSCT for multiple myeloma (MM). This study demonstrated an improved progression-free and overall survival for MM patients receiving lenalidomide maintenance therapy after autologous HSCT. Our team has developed a systematic approach to the evaluation and treatment of HSCT patients with a specific focus on predicting and minimizing treatment-related mortality (TRM). We participate with a core group of basic science and clinical researchers who are committed to the investigation of the complications of autologous and allogeneic HSCT and to the developing novel approaches to improve outcomes.
Philip McCarthy, MD, Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, provides an overview of the utilization of T-Cell therapies for malignant diseases, with an emphasis on immune effector therapy.